Autolus Therapeutics to Participate in Upcoming Investor Conferences
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Autolus Therapeutics (Nasdaq: AUTL) will participate in two investor conferences in April 2026. The CEO, Dr. Christian Itin, will present at the 25th Annual Needham Virtual Healthcare Conference on April 13, 2028 at 10:15am EDT / 3:15pm BST. A webcast and 90-day replay will be available on the company's Events page. Management will also host investor meetings at the Van Lanschot Kempen Life Sciences Conference in Amsterdam on April 16, 2026.
Details
News Market Reaction – AUTL
On Apr 7, the day this news came out, AUTL closed 2.16% below the previous close.
Data tracked by StockTitan Argus for the Apr 7 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
LONDON and GAITHERSBURG, Md., April 07, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announced that the Company will participate in two upcoming investor conferences.
25th Annual Needham Virtual Healthcare Conference
Date and time: April 13, 2028; 10:15am EDT / 3:15pm BST
Presenter: Chief Executive Officer Dr. Christian Itin
A webcast of the presentation will be available on the “Events” page in the “Investor Relations & Media” section of the Company’s website at https://www.autolus.com/investor-relations-media/events/. A replay of the webcast will be archived on the Company’s website for 90 days following the presentation.
Van Lanschot Kempen Life Sciences Conference
Management to host investor meetings
Date: April 16, 2026
Location: Amsterdam
About Autolus Therapeutics plc
Autolus Therapeutics plc (Nasdaq: AUTL) is a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation T cell therapies and candidates for the treatment of cancer and autoimmune disease. Using a broad suite of proprietary and modular T cell programming technologies, Autolus is engineering precisely targeted and controlled T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and eliminate these cells. Autolus has a marketed therapy, AUCATZYL®, and a pipeline of product candidates in development for the treatment of hematological malignancies, solid tumors and autoimmune diseases. For more information, please visit www.autolus.com.
Contact:
Amanda Cray
+1 617-967-0207
a.cray@autolus.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.